A Multidisciplinary Approach to Treating Resectable NSCLC
Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.
Belzutifan Significantly Improves PFS Vs Everolimus in Clear Cell RCC
Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.
CB-012 Earns FDA Fast Track Status in R/R Acute Myeloid Leukemia
Treatment with CB-012 for patients with relapsed/refractory acute myeloid leukemia is under evaluation as part of the phase 1 AMpLify trial.
Cancer Rehabilitation Medicine: “Bridging the Gap” With Supportive Care
Cancer rehabilitation medicine may help bridge a gap in oncology care, according to Jessica Cheng, MD.
Niraparib May Show “Meaningful” Benefits in MGMT Unmethylated Glioblastoma
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Prior Encouraging Data Support Further Study of Niraparib in Glioblastoma
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma
“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.
Encorafenib Combo Earns European Approval in Advanced BRAF+ NSCLC
Data from the phase 2 PHAROS trial support the European Commission’s approval of encorafenib/binimetinib in NSCLC harboring a BRAF V600E mutation.
Adjuvant Chemotherapy May Have Survival Benefit in Stage III Locally Advanced NSCLC
Favorable recurrence-free survival and overall survival outcomes were not observed in the overall patient cohort receiving adjuvant chemotherapy for advanced NSCLC.
Trials Evaluating Bispecific Antibodies in Earlier Therapy Lines Show Promise
Surbhi Sidana, MD, spoke about multiple myeloma developments with the potential to impact clinical practice, particularly early line use of bispecific antibodies.
1 Centrally Located Breast Cancer Is More Aggressive in Bahraini Patients
Moving the Needle Forward in Cancer Rehabilitation
It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.
Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups
Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.
Linvoseltamab Achieves Deep and Durable Responses in R/R Multiple Myeloma
Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma.
Cancer Rehabilitation May Be Appropriate for Every Type of Cancer
Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.
Aggressive Supportive Care Following Novel Agents May Reduce Infection
Surbhi Sidana, MD, discussed outpatient supportive care for patients following immunotherapy treatment for hematologic cancers.
Implementing Cancer Rehabilitation to Improve Quality of Life
Jessica Cheng, MD, noted that working with patients in the field of cancer rehabilitation to improve recovery times brings her joy.
2 Is Laterality in Breast Cancer Still Worth Studying? Local Experience in Bahrain
Olaparib Combo May Show Clinical Benefit in Advanced HER2+ Breast Cancer
The OPHELIA trial assessed the efficacy and safety of olaparib plus trastuzumab in HER2-positive advanced breast cancer with germinal BRCA mutations.
sNDA of Fruquintinib Combo Withdrawn in China for Second-Line Gastric/GEJ Cancer
Second-line fruquintinib plus paclitaxel did not sustain sufficient efficacy for patients with advanced gastric or GEJ adenocarcinoma to support approval in China.
Oxygen-Enhanced MRI May Reduce Radiotherapy Exposure in Tumors with Hypoxia
A clinical trial evaluated the ability of oxygen-enhanced MRI-derived hypoxic volume to detect radiotherapy-induced hypoxia modification.
Treatment-Responsive Acute Graft-versus-Host Disease After Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes
A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.
The Best of CAR T at the 2024 Tandem Meetings
The Best of CAR T at the 2024 Tandem Meetings Webinar Series, which aired on June 27, 2024, aimed to provide a comprehensive overview of the latest advancements and research in CAR T cell therapy.
3 Gender Disparities in the National Institutes of Health Funding for Breast Cancer
4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells
Lazertinib Shows Encouraging Intracranial ORR in EGFR NSCLC with CNS Metastases
Regardless of T790M status, lazertinib hindered the progression of intracranial metastases after unsuccessful EGFR TKI treatment in patients with EGFR-mutated NSCLC.
NSCLC and CSCC Trials Discontinued Due to No Efficacy Benefit With Pembrolizumab/SBRT
Trials assessing NSCLC and cutaneous squamous cell carcinoma were discontinued due to no benefit observed or improvement noted with the primary end points.
5 Predictors of Axillary Complete Pathologic Response in Hormone Receptor–Positive, HER2-Negative, Clinically Node-Positive Breast Cancer
Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer
The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.
European Commission Approves Amivantamab Combo for EGFR-mutated NSCLC
The EGFR-MET bispecific antibody amivantamab in combination with chemotherapy yielded a survival benefit compared with chemotherapy alone for EGFR-mutated NSCLC.
![“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8b007a323176820eb0754e84186341fe7ca44ae4-350x350.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.")
